Close Menu

NEW YORK – 23andMe has laid off approximately 100 employees, about 14 percent of its workforce, the direct-to-consumer genetic testing company confirmed on Thursday.

According to a spokesperson, the layoffs occurred across the company's consumer business, which is being restructured, but did not affect its therapeutics business.

Going forward, 23andMe will focus its activities on its core businesses, consumer genomics and therapeutics, and plans to scale back on non-core activities, such as clinical trials, the spokesperson said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.